title: Supraventricular arrhythmias in children and young adults with implantable cardioverter defibrillators.
abstract: BACKGROUND
  Rapidly conducted supraventricular tachycardias (SVTs) can lead to inappropriate device therapy in implantable cardioverter defibrillator (ICD) patients. We sought to determine the incidence of SVTs and the occurrence of inappropriate ICD therapy due to SVT in a pediatric and young adult population.
  
  
  RESULTS
  We undertook a retrospective review of clinical course, Holter monitoring, and ICD interrogations of patients receiving ICD follow-up at our institution between March 1992 and December 1999. Of 81 new ICD implantations, 54 eligible patients (median age 16.5 years, range 1 to 48) were identified. Implantation indications included syncope and/or spontaneous/inducible ventricular arrhythmia with congenital heart disease (30), long QT syndrome (9), structurally normal heart (ventricular tachycardia/ventricular fibrillation [VT/VF]) (7), and cardiomyopathies (7). Sixteen patients (30%) received a dual-chamber ICD. SVT was recognized in 16 patients, with 12 of 16 having inducible or spontaneous atrial tachycardias. Eighteen patients (33%) received > or =1 appropriate shock(s) for VT/VF; 8 patients (15%) received inappropriate therapy for SVT. Therapies were altered after an inappropriate shock by increasing the detection time or rate and/or increasing beta-blocker dosage. No single-chamber ICD was initially programmed with detection enhancements, such as sudden onset, rate stability, or QRS discriminators. Only one dual-chamber defibrillator was programmed with an atrial discrimination algorithm. Appropriate ICD therapy was not withheld due to detection parameters or SVT discrimination programming.
  
  
  CONCLUSIONS
  SVT in children and young adults with ICDs is common. Inappropriate shocks due to SVT can be curtailed even without dual-chamber devices or specific SVT discrimination algorithms.
authors.affiliation: Department of Cardiology, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Love
authors.forename: K S
authors.initials: KS
authors.lastname: Barrett
authors.forename: M E
authors.initials: ME
authors.lastname: Alexander
authors.forename: L M
authors.initials: LM
authors.lastname: Bevilacqua
authors.forename: M R
authors.initials: MR
authors.lastname: Epstein
authors.forename: J K
authors.initials: JK
authors.lastname: Triedman
authors.forename: E P
authors.initials: EP
authors.lastname: Walsh
authors.forename: C I
authors.initials: CI
authors.lastname: Berul
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000465:Algorithms; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001900:Boston / Q000453:epidemiology; D017115:Catheter Ablation; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D017147:Defibrillators, Implantable / Q000009:adverse effects; D022062:Electrophysiologic Techniques, Cardiac; D004868:Equipment Failure; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D013617:Tachycardia, Supraventricular / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000150:complications / Q000175:diagnosis / Q000628:therapy
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents